about
Amelioration of amyloid-β-induced deficits by DcR3 in an Alzheimer's disease model.Rapid generation of amyloid from native proteins in vitro.Thermodynamic study of transthyretin association (wild-type and senile forms) with heparan sulfate proteoglycan: pH effect and implication of the reactive histidine residue.Binding with nucleic acids or glycosaminoglycans converts soluble protein oligomers to amyloid.Transgenic over-expression of mammalian heparanase delays prion disease onset and progression.Nucleic acid-containing amyloid fibrils potently induce type I interferon and stimulate systemic autoimmunity.A novel method for quantifying peripheral tissue amyloid load by using the radiolabeled amyloidophilic peptide, p5.The effect of glycosaminoglycans (GAGs) on amyloid aggregation and toxicity.Polyanion binding accelerates the formation of stable and low-toxic aggregates of ALS-linked SOD1 mutant A4V.S100A6 amyloid fibril formation is calcium-modulated and enhances superoxide dismutase-1 (SOD1) aggregation.Targeting heparin and heparan sulfate protein interactions.Secondary structure propensity and chirality of the amyloidophilic peptide p5 and its analogues impacts ligand binding - In vitro characterization.Critical Influence of Cosolutes and Surfaces on the Assembly of Serpin-Derived Amyloid Fibrils.HS3ST2 expression is critical for the abnormal phosphorylation of tau in Alzheimer's disease-related tau pathology.Amyloid fibrils have additional componentsStructural requirements of glycosaminoglycans for facilitating amyloid fibril formation of human serum amyloid A
P2860
Q30846817-4D33F66A-CA7F-4F4A-985F-7D84B6B79410Q33709292-07E0D41F-72C2-4807-9940-5900D552022FQ35254474-4E8F783E-0285-4BEE-8634-EFE7D897EE8CQ35643865-1E9D18B1-2A87-4EA6-9687-52CF0EB95FB6Q35940703-06A7E6E6-ABBA-48FB-B99C-4CAE63951152Q36221861-D4E52DE9-C096-4DE4-896C-60ADEF494536Q37010197-68CE043F-54D4-4900-9CC7-4F559AFFCD41Q38343014-EB6A0A8E-E860-49CD-8C2D-4FE7FB8F02EEQ38956652-F1587312-5BA2-4500-9B8B-63AE335F8AEEQ39257498-57026042-1DE1-4DFD-922D-3A2EE5A45CA0Q39399937-D4A0D71A-B9BB-47F7-A6C1-4625470A98B9Q41682767-CBA26AAF-FAD3-4DFF-8C9D-D21489295CD9Q46323407-350C40F7-F0B3-47BD-9FEF-160B11055B6BQ48246914-1C55C369-5E09-4C39-89CE-1B696847A1CDQ50296949-76FE3A13-6E45-4E6E-9FAB-CC89E4195329Q58134438-8DEAE303-DEA5-4C9E-9456-FA54E80B5A33
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Heparan sulfate proteoglycans in amyloidosis.
@en
Heparan sulfate proteoglycans in amyloidosis.
@nl
type
label
Heparan sulfate proteoglycans in amyloidosis.
@en
Heparan sulfate proteoglycans in amyloidosis.
@nl
prefLabel
Heparan sulfate proteoglycans in amyloidosis.
@en
Heparan sulfate proteoglycans in amyloidosis.
@nl
P1476
Heparan sulfate proteoglycans in amyloidosis.
@en
P2093
Jin-Ping Li
Xiao Zhang
P304
P356
10.1016/S1877-1173(10)93013-5
P577
2010-01-01T00:00:00Z